| abstract |
The invention provides use of an agent which lowers levels of 11β-HSD1 in the manufacture of a composition for the promotion of an atheroprotective lipid profile, for reducing cardiovascular disease risk, for increasing insulin sensitivity or promoting glucose tolerance, for increasing metabolic rate and prevent or reverse body weight gain, for preventing the side-effects of glucocorticoid therapy, reducing cholesterol storage in macrophages or for reducing intrahepatic fat levels (in steatohepatitis, cirrhosis, or fatty liver). This agent may be used in combination with PPAR-alpha or gamma agonists (such as fibrates), appetite suppressants, antiobesity drugs..., or, possibly with glucocorticoids in the treatment of inflammation, or with metformin. It can be used in the treatment of atherosclerosis, metabolic syndrome, diabetes or obesity. |